Compounded Peptides ·
Following FDA's October 2024 resolution of the tirzepatide shortage, compounding pharmacies responded with a range of strategies. Some discontinued tirzepatide compounding immediately. Others filed nominations with FDA to add tirzepatide to the 503A bulks list — a pathway that has so far been unsuccessful. A third group pivoted to 'personalized' tirzepatide formulations with supplemental ingredients, arguing those represented clinically distinct products under 503A. A fourth group continued tirzepatide compounding openly, sometimes citing pending litigation as a basis for continued operation. Each of these strategies has produced distinct enforcement trajectories through 2025 and into early 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.